Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Wilson, JM; Mukherjee, S; Chu, KY; Brunner, TB; Partridge, M; Hawkins, M.
Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
Radiat Oncol. 2014; 9:146
Doi: 10.1186/1748-717X-9-146
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Brunner Thomas Baptist
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The best method of identifying regions within pancreatic tumours that might benefit from an increased radiotherapy dose is not known. We investigated the utility of pre-treatment FDG-PET in predicting the spatial distribution of residual metabolic activity following chemoradiotherapy (CRT) in locally advanced pancreatic cancer (LAPC). METHODS: 17 patients had FDG-PET/CT scans at baseline and six weeks post-CRT. Tumour segmentation was performed at 40% and 50% of SUVmax at baseline and 60%, 70%, 80% and 90% post-CRT. FDG-PET scans were non-rigidly registered to the radiotherapy planning CT using the CT component of the FDG-PET/CT. Percentage overlap of the post-CRT volumes with the pre-CRT volumes with one another and the gross tumour volume (GTV) was calculated. RESULTS: SUVmax decreased during CRT (median pre- 8.0 and post- 3.6, p < 0.0001). For spatial correlation analysis, 9 pairs of scans were included (Four were excluded following complete metabolic response, one patient had a non-FDG avid tumour, one had no post-CRT imaging, one had diffuse FDG uptake that could not be separated from normal tissues and one had an elevated blood glucose). The Pre40% and 50% of SUVmax volumes covered a mean of 50.8% and 30.3% of the GTV respectively. The mean% overlap of the 90%, 80%, 70%, 60% of SUVmax post-CRT with the Pre40% and Pre50% volumes were 83.3%, 84.0%, 83.7%, 77.9% and 77.8%, 69.9%, 74.5%, 64.8% respectively. CONCLUSIONS: Regions of residual metabolic activity following CRT can be predicted from the baseline FDG-PET and could aid definition of a biological target volume for non-uniform dose prescriptions.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - diagnosis, metabolism, therapy
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Chemoradiotherapy - administration & dosage
- Cisplatin - administration & dosage
- Clinical Trials, Phase II as Topic - administration & dosage
- Deoxycytidine - administration & dosage, analogs & derivatives
- Fluorodeoxyglucose F18 - administration & dosage
- Follow-Up Studies - administration & dosage
- Humans - administration & dosage
- Multimodal Imaging - administration & dosage
- Neoplasm Staging - administration & dosage
- Pancreatic Neoplasms - diagnosis, metabolism, therapy
- Positron-Emission Tomography - statistics & numerical data
- Prognosis - administration & dosage
- Radiopharmaceuticals - administration & dosage
- Radiotherapy Dosage - administration & dosage
- Radiotherapy Planning, Computer-Assisted - administration & dosage
- Tomography, X-Ray Computed - statistics & numerical data
- Find related publications in this database (Keywords)
- Pancreatic cancer
- PET-CT
- Residual metabolic activity
- Intra-tumour heterogeneity
- Biological target volume